Parsey Merdad's Form 4 filing
Gilead Sciences, Inc. (GILD) · filed Nov 29, 2024
- Accession no.
- 0001127602-24-028232
- Filed
- Nov 29, 2024
- Trade date
- Nov 27, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 2 derivative transactions. Open-market sales total $15.1M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Parsey MerdadCIK 0001792150 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 27, 2024 | Common Stock | MOption exerciseAcquired | +57,294 | $57.92 | +$3,318,468.48 | 156,893 | Direct | |
| Nov 27, 2024 | Common Stock | MOption exerciseAcquired | +88,119 | $65.38 | +$5,761,220.22 | 245,012 | Direct | |
| Nov 27, 2024 | Common Stock | SSaleDisposed | −57,294 | $91.79F1 | −$5,259,016.26 | 187,718 | Direct | |
| Nov 27, 2024 | Common Stock | SSaleDisposed | −88,119 | $92.00 | −$8,106,948 | 99,599 | Direct | |
| Nov 27, 2024 | Common Stock | SSaleDisposed | −5,200 | $91.80F2 | −$477,360 | 94,399 | Direct | |
| Nov 27, 2024 | Common Stock | SSaleDisposed | −3,199 | $91.80F3 | −$293,668.2 | 91,200 | Direct | |
| Nov 27, 2024 | Common Stock | SSaleDisposed | −10,399 | $92.00 | −$956,708 | 80,801 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 27, 2024 | Common Stock | MOption exerciseDisposed | −57,294 | $0.00 | $0 | 64,376 | Direct | |
| Nov 27, 2024 | Common Stock | MOption exerciseDisposed | −88,119 | $0.00 | $0 | 196 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Sale prices reported for the transactions reported here range from $91.451 to $92.095. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
Referenced by the price of 1 transaction in Table I.
- F2
Sale prices reported for the transactions reported here range from $91.458 to $92.04. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
Referenced by the price of 1 transaction in Table I.
- F3
Sale prices reported for the transactions reported here range from $91.451 to $92.035. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
Referenced by the price of 1 transaction in Table I.